We are live on ! Find out more
TMO icon

Thermo Fisher Scientific

1,159 hedge funds and large institutions have $59.1B invested in Thermo Fisher Scientific in 2017 Q2 according to their latest regulatory filings, with 93 funds opening new positions, 409 increasing their positions, 490 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 53

38% more funds holding in top 10

Funds holding in top 10: 6590 (+25)

12% more capital invested

Capital invested by funds: $52.8B → $59.1B (+$6.31B)

2% more funds holding

Funds holding: 1,1351,159 (+24)

1.4% less ownership

Funds ownership: 87.93%86.53% (-1.4%)

17% less repeat investments, than reductions

Existing positions increased: 409 | Existing positions reduced: 490

40% less call options, than puts

Call options by funds: $122M | Put options by funds: $202M

Holders
1,159
Holders Change
+24
Holders Change %
+2.11%
% of All Funds
28.89%
Holding in Top 10
90
Holding in Top 10 Change
+25
Holding in Top 10 Change %
+38.46%
% of All Funds
2.24%
New
93
Increased
409
Reduced
490
Closed
53
Calls
$122M
Puts
$202M
Net Calls
-$80.7M
Net Calls Change
-$37.1M
Name Holding Trade Value Shares
Change
Change in
Stake
LFM
401
Lumina Fund Management
New York
$7.24M
OPERF
402
Oregon Public Employees Retirement Fund
Oregon
$7.19M
SIA
403
Sit Investment Associates
Minnesota
$7.1M -$382K -2,273 -5%
PBT
404
Pictet Bank & Trust
Bahamas
$7.05M -$3.3M -19,645 -33%
AIA
405
Avalon Investment & Advisory
Texas
$6.94M -$145K -865 -2%
SAM
406
Securian Asset Management
Minnesota
$6.9M +$49.9K +297 +0.8%
HCMT
407
Highland Capital Management (Tennessee)
Tennessee
$6.88M +$295K +1,756 +5%
EAM
408
EULAV Asset Management
Florida
$6.86M
MKC
409
M. Kraus & Co
Vermont
$6.85M -$14.3K -85 -0.2%
GL
410
GLG LLC
New York
$6.82M +$4.28M +25,459 +187%
RWM
411
RKL Wealth Management
Pennsylvania
$6.76M -$1.01M -6,026 -13%
MSU
412
Mizuho Securities USA
New York
$6.75M +$6.5M +38,700 New
CS
413
Credential Securities
$6.74M +$814K +4,844 +14%
CT
414
Coastline Trust
Rhode Island
$6.74M -$148K -880 -2%
Capstone Investment Advisors
415
Capstone Investment Advisors
New York
$6.73M -$3.65M -21,751 -36%
TAF
416
Tredje AP-fonden
Sweden
$6.7M -$905K -5,385 -12%
MAM
417
Mastrapasqua Asset Management
Tennessee
$6.66M -$147K -873 -2%
SAM
418
Steinberg Asset Management
New York
$6.65M -$532K -3,170 -8%
ProShare Advisors
419
ProShare Advisors
Maryland
$6.63M -$191K -1,138 -3%
SCA
420
Stonebridge Capital Advisors
Minnesota
$6.56M -$58.1K -346 -0.9%
LOAMS
421
Lombard Odier Asset Management (Switzerland)
Switzerland
$6.56M +$2.22M +13,200 +54%
PPSG
422
Princeton Portfolio Strategies Group
New Jersey
$6.56M +$125K +744 +2%
MCA
423
Morris Capital Advisors
Pennsylvania
$6.53M -$423K -2,520 -6%
TCOV
424
Trust Company of Vermont
Vermont
$6.5M +$283K +1,684 +5%
PAM
425
Panagora Asset Management
Massachusetts
$6.46M +$1.3M +7,746 +26%

TMO Hedge Fund Activity: Q2 2017 in Review

1,159 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Thermo Fisher Scientific (TMO) for Q2 2017, worth a combined $59.1B — up 12% from $52.8B a quarter earlier.

Buyers outnumbered sellers: 93 funds opened new TMO positions and 53 closed out — a net gain of 40 holders — while 409 added to existing stakes and 490 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $667M. The largest seller was T. Rowe Price Associates, cutting an estimated $557M.

  • 1,159 institutional investors held Thermo Fisher Scientific (TMO) as of Q2 2017, up from 1,135 in Q1 2017.
  • Funds reported $59.1B of Thermo Fisher Scientific stock for Q2 2017, up 12% quarter-over-quarter.
  • 93 funds opened new Thermo Fisher Scientific positions in Q2 2017 and 53 closed out, a net change of +40 holders.
  • The largest Thermo Fisher Scientific buyer in Q2 2017 was Capital Research Global Investors, an estimated $667M added.
  • The largest Thermo Fisher Scientific seller in Q2 2017 was T. Rowe Price Associates, an estimated $557M sold.

Based on aggregated 13F filings for Q2 2017.